CSTL Castle Biosciences

Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a second consecutive Arizona Top Workplace award from AZ Central, the digital home of The Arizona Republic newspaper.

“We are thrilled to have once again been recognized as a Top Workplace in Arizona; this award is especially meaningful as it is based on feedback from our employees and is a testament to our unique workplace culture,” said Derek Maetzold, president and chief executive officer at Castle Biosciences. “We are truly grateful for our exceptional Castle team members who believe in our vision of keeping people first and show up each day, passionate about improving patient care.”

Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures 15 culture drivers that are indicative of successful organizations, such as alignment, execution and connection. Castle’s survey participation rate of 89% and employee engagement score of 81% were both well above the benchmark averages of 59% and 53%, respectively, for other similar healthcare companies participating in the Top Workplaces program.

Earlier this year, Castle also earned five Top Workplaces Culture Excellence Awards for continued excellence in the following areas of its workplace culture:

  • Innovation, for creating a culture where new ideas are encouraged, which helps employees to reach their full potential and benefits performance.
  • Work-Life Flexibility, for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
  • Compensation & Benefits, for providing packages employees believe are fair for the work being done and compared to others in the industry.
  • Leadership, for organizational leaders who inspire confidence in employees and the company direction, listening to what matters most to employees and using that insight in decision making.
  • Purpose & Values, for successfully communicating the company mission and integrating those aspirations into the culture.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to work together.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 16 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

EN
17/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

 PRESS RELEASE

Castle Biosciences Enters Collaboration and License Agreement with Sci...

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance Spectroscopy technology which include...

 PRESS RELEASE

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Particip...

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will ...

 PRESS RELEASE

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored ...

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguish...

 PRESS RELEASE

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improv...

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 Ameri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch